NEW YORK – Carsgen Therapeutics on Monday said it plans to seek approval in China for its autologous CAR T-cell therapy satricabtagene autoleucel (satri-cel) in previously treated patients with ...

The firm said it plans to share data with regulatory agencies from the Phase III STEER trial after it met its primary endpoint.

Sangamo is seeking new partners to continue advancing giroctocogene fitelparvovec, which reported positive Phase III results this year.

Concr will use data collected by CariGenetics to create AI models to advance precision medicine for triple-negative breast cancer patients in the Caribbean.

The FDA granted priority review to the company's avutometinib-defactinib application and expects to decide on approval in June 2025.